Compare PRTA & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTA | BNTC |
|---|---|---|
| Founded | 2012 | 1995 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.8M | 405.7M |
| IPO Year | N/A | N/A |
| Metric | PRTA | BNTC |
|---|---|---|
| Price | $9.12 | $12.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $18.86 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 729.9K | 218.9K |
| Earning Date | 02-19-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,786,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $819.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.32 | $9.70 |
| 52 Week High | $16.67 | $17.15 |
| Indicator | PRTA | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 40.87 | 44.07 |
| Support Level | $8.95 | $11.21 |
| Resistance Level | $9.47 | $12.71 |
| Average True Range (ATR) | 0.37 | 0.90 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 22.61 | 31.18 |
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.